These preclinical findings were translated into the clinical setting where we show that MYC and MCL1 mRNA levels are downregulated in the blood of DH-DLBCL but that also this mechanism of action is confirmed in patients with other MYC+ NHL across various indications and not limited to DH-DLBCL. This evidence concerns the gene MYC and non-Hodgkin lymphoma.